Overview
HBOT is UHMS-approved for idiopathic sudden sensorineural hearing loss when initiated within 2 weeks of onset. Combination with corticosteroids yields the best outcomes. The mechanism involves overcoming cochlear hypoxia. Added to CMS coverage in 2021.
Idiopathic sudden sensorineural hearing loss (ISSNHL) is defined as hearing loss of ≥30 dB over three contiguous frequencies, developing within 72 hours, with no identifiable cause. Standard first-line treatment is oral or intratympanic corticosteroids. HBOT is an evidence-based adjunct that improves hearing recovery when added to steroid therapy, particularly in severe cases.
The time window matters. Treatment initiated within 2 weeks of onset shows the strongest benefit. Treatment initiated after 1 month shows little benefit. UHMS and CMS coverage criteria reflect this time-sensitive window.
CMS added ISSNHL to covered indications in 2021 following a formal reconsideration. Coverage requires initiation within 14 days of onset and specific documentation of hearing loss severity and steroid trial.
How HBOT Works for This Condition
The inner ear has high metabolic demand and limited collateral circulation, making it vulnerable to ischaemic injury. ISSNHL is hypothesised to involve cochlear microvascular compromise. HBOT elevates plasma oxygen delivery to cochlear structures, supporting hair cell survival during the critical early window. Combined with corticosteroid anti-inflammatory effects, HBOT appears to improve the proportion of patients who recover functional hearing.
GRADE Evidence Rating
Bennett 2012 Cochrane shows PTA improvement when HBOT delivered within 2 weeks. UHMS added 2019.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Low |
| Consistency | Mostly consistent |
| Directness | Direct |
| Precision | Moderate |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 10–20 sessions at 2.0–2.4 ATA, 90 minutes each |
|---|---|
| Evidence level | Moderate — UHMS approved |
| FDA status | FDA-approved indication |
Standard ISSNHL HBOT: 2.0–2.4 ATA sessions, 10–20 total, 5 days per week. Initiated as soon as possible after diagnosis. Combined with oral prednisone or intratympanic steroid injection per otolaryngology protocol.
Evidence Base
Bennett et al. 2012 Cochrane review supported HBOT as adjunct to steroids in SSNHL. Multiple RCTs and case series. UHMS Tier 1 approved; CMS covered since 2021.
Cautions & Considerations
- Time-critical — must initiate within 14 days (CMS) and ideally within days of onset.
- Adjunct to — not replacement for — corticosteroid therapy.
- Requires otolaryngology referral and audiometry.
- Standard HBOT contraindications apply.
Key Research & References
- Bennett et al. 2012 (Cochrane)
- Alimoglu et al. 2011
- UHMS Indications Manual
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
How quickly after hearing loss must HBOT start?
As soon as possible. CMS coverage requires initiation within 14 days. Earlier is better. After 1 month, HBOT benefit is minimal.
Does HBOT work without steroids?
The strongest evidence is for HBOT combined with corticosteroids. Isolated HBOT has less data; combination therapy is the clinical standard.
Can HBOT reverse established hearing loss?
HBOT can improve hearing recovery when started within the time-sensitive window. Established hearing loss months after onset is not reversed by HBOT.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.